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Background & Evidence for Problem 
Chlamydia trachomatis, also known as chlamydia, is the most common bacterial sexually 
transmitted infection (STI) worldwide. Rates of chlamydia have been on the rise since it became 
a reportable disease to the Center of Disease Control (CDC) in 1984. In 2017, 1,708,569 cases 
were reported to the CDC, which is the highest amount of cases ever reported (Center for 
Disease Control, 2017). Chlamydia trachomatis is a bacterium that is highly curable with 
antibiotics if treated early. Untreated, this bacterium can cause pelvic inflammatory disease and 
uterine scarring for women, leading to infertility or ectopic pregnancies. It can also be a 
precursor for cervical cancer and endometriosis in women, and potentially transferred to 
offspring during childbirth (Malhotra, Sood, Mukherjee, Muralidhar, & Bala, 2013). Both men 
and women can contract chlamydia and are often asymptomatic. Potential signs and symptoms 
are pain with intercourse, dysuria, and abnormal vaginal or penial discharge. Early detection and 
screening of chlamydia is important to prevent transmission and secondary complications. 
Women who are between the ages of 15 to 24 years old and sexually active are considered to be 
the highest risk population due to multiple partners (Navarro, Jolly, Nair, & Chen, 2002). Other 
risk factors of chlamydia include unprotected intercourse, inconsistent use of barriers, minorities, 
low socioeconomic status, new or multiple sexual partners, cervical ectopy, military men under 
the age of 30, men in the prison system, and all genders in the juvenile detention system 
(Keegan, Diedrich, & Peipert, 2014).  
The United States Preventative Services Task Force (USPSTF) and CDC both 
recommend routine screening for chlamydia for sexually active females under the age of 25 
years old and 25 years old or older if at increased risk (USPSTF, 2016). The CDC showed that 
the highest risk group for chlamydia were females ages 20-24 due to the fact that their reported 
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chlamydia rates have been consistently higher than other age groups. In 2016, 3,779 per 100,000 
females were diagnosed with Chlamydia among this age group. The second highest risk group 
includes females ages 15-19 at 3,070.9 per 100,000 total chlamydia cases (CDC, 2017). Overall 
there were 10,516.2 per 100,000 cases total for females of all age groups. 
When given the opportunity in acute or urgent care, chlamydia should be considered 
when females present with urinary signs and symptoms. Many patients, especially in the high-
risk groups, do not have a primary care provider or see a primary care provider on a routine 
basis. These patients do not have access or confidence in primary care and choose to visit urgent 
cares and emergency departments for basic healthcare needs (Coster, Turner, Bradbury, & 
Cantrell, 2017). A meta-analysis by Tomas et al. (2015), demonstrated a high rate of STIs in 
emergency departments when presenting with urinary problems. Of 264 women studied 
presenting with urinary symptoms to emergency departments, 60 had one or more positive exams 
for STIs (Tomas, Getman, Donskey, & Hecker, 2015). Unless testing for common STIs, many of 
these patients with urinary symptoms would be treated as urinary tract infections. Of the 60 
diagnosed with a STI, 22 females were inappropriately given antibiotics for a urinary tract 
infection and 13 of these patients were positive for chlamydia (Tomas et al., 2015). Another 
meta-analysis by Goya et al. (2016) in multiple urgent care settings, screened asymptomatic 
adolescents ages 14-21 years old for STIs and 4.9% came back positive with at least one STI 
(Goyal, Teach, Badolato, Trent, & Chamberlain, 2016).  
Being tested for STIs can be embarrassing and can conflict with a culture of sexual 
privacy even though prevention should be accepted as a critical part of a healthy lifestyle. 
Practitioners and medical staff can strongly influence a patient’s willingness to get tested by 
providing safe, open dialogue and an emphasis on education. A randomized control trial by 
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McNulty (2014), studied about 160 general practitioner practices to demonstrate chlamydia 
screening behavior changes pre and post practice-based education for patients and staff. 
Screening rates for women 15-24 years old increased by 2.33% after implementation of the 
educational intervention (McNulty et al,. 2014). 
There are several diagnostic laboratory studies to test for chlamydia that range in 
collection technique, cost, processing time, sensitivity, and specificity. The most accurate test 
and the one recommended by the CDC is nucleic acid amplification testing. Nucleic acid 
amplification testing can be completed on a first void urine specimen or by vaginal swab. 
Collection of the vaginal swabs can be performed by the provider or the patient, but sensitivity 
and specificity of the test is higher with patient collected swabs (Meyer, 2016). Nucleic acid 
amplification testing has a sensitivity of 86% and specificity of 97%. Clean catch urine 
specimens have the ability to screen for a UTI and chlamydia at the same time but have a 
sensitivity of 72% when screening for chlamydia (United States Preventive Services Task Force, 
2014). Clean catch urine specimens have a lower sensitivity rate when compared to other 
methods (Meyer, 2016). 
In a 10-month retrospective chart review, only 8 patients presented to the clinic project 
site with urinary symptoms and none of them were screened for chlamydia. This sample number 
was low because the practice site had recently opened and was still gaining clientele. In addition, 
the computer charting system changed during this period of time and patients may not have been 
transferred over to the newest software for review. The practice site did not routinely screen for 
chlamydia when females presented with dysuria, urinary frequency, or urinary tract infection 
symptoms. Women presenting with dysuria and signs and symptoms of a urinary tract infection 
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were only being treated for a urinary tract infection (UTI). The laboratory screening method for a 
UTI included a clean catch urine.  
 
Purpose 
The purpose of this evidenced-based practice project was to increase chlamydia 
prescreening and screening for females, ages 15-24, presenting to urgent care with urinary 
symptoms.  
Evidence Based Project Model 
The ACE Star Model was used as the framework to guide this project. This model 
focuses heavily on having a consistent body of knowledge that supports change (Stevens, 2012). 
It uses translational science to implement practice guidelines based on current research. The 
ACE Star Model is depicted as a star with five points illustrating the main stages of transforming 
an evidence-based project including knowledge discovery, evidence synthesis, translation into 
practice recommendations, integration into practice, and evaluation (Stevens, 2004). 
All five of the ACE Star Model stages were used in this evidence-based practice project. 
Knowledge discovery comprised of evaluating clinic site needs with stakeholders and a chart 
review to determine the study site’s practice in screening for chlamydia. Evidence synthesis 
included extensive literature review to review the strength of evidence supporting the project and 
to determine appropriate chlamydia screening techniques. Translation into practice took place 
when the site stakeholders understood the scope of the problem and were supportive of 
integrating evidenced-based chlamydia screening in this setting. Integration into practice 
included incorporating the prescreening questions into the electronic health record. Lastly, 
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evaluation was conducted with all stakeholders to increase awareness of prescreening and 
screening and the feasibility of using higher yield collection methods.   
 
Project Plan Process 
A chart review over 10 months was completed to gain a better understanding of the need 
for chlamydia screening in this Southern California urgent care setting.  Data obtained revealed 
that high risk females presenting with symptoms of UTI were not screened for chlamydia. The 
evidenced based intervention included incorporating a chlamydia screening template into the 
electronic health record (EHR) to prescreen high risk women according to the CDC and 
USPSTF.  Women ages 15 to 24 years old with a chief complaint of dysuria or urinary frequency 
were asked four questions by a medical assistant prior to being seen by the provider. These 
question options were “yes”, “no”, or “decline to answer” and were determined to be 
“prescreening” questions because the answer determined if screening for chlamydia was 
appropriate for the individual. The specific questions include:  
• Are you sexually active?  
• Have you ever been screened for STIs?  
• Have you been screened within the past year for STIs?  
• Any new partners since last screened for STIs?  
These questions were all added to the EHR as part of the dysuria and urinary frequency 
templates. By adding these questions to the template for females 15 to 24 years old with dysuria 
and urinary frequency, it served as an alert for a healthcare staff to enter the answers to the pre-
screening questions into the mandated fields. Screening criteria with a urine test included 
females younger than 25 who were sexually active and had not been tested for STIs in the past 
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year or who had a new sexual partner since last being tested. If the patient was screened within 
the last year with no new partners or not sexually active, chlamydia screening was not 
recommended.  
Screening consisted of a clean catch urine laboratory test used to screen for UTI, 
chlamydia and gonorrhea. Education to providers and staff was performed prior to project 
implementation that outline how to use the mandatory prescreening questions to encourage 
chlamydia screening efforts, patient comfort, and an appropriate treatment plan. Institutional 
review board approval was obtained from the academic review board prior to the initiation of the 
project. All data collected were cleansed of patient identifiers.  
Post-implantation data were obtained from the EHR for over a 7-month period including 
gender, age, answers to the chlamydia prescreening questionnaire, results of chlamydia lab tests, 
insurance name or fee for service, the physician providing care, results of the urinalysis, and 
diagnosis provided.   
Evaluation Results 
Pre-implementation data obtained included 8 female patients between the ages of 13 and 
24 years old who were seen for dysuria, urinary tract infections, or urinary frequency. Zero of the 
8 patients seen were prescreened, screened, or diagnosed with chlamydia.  Post-implementation 
data included 481 female patients that presented for dysuria, urinary tract infection, and urinary 
frequency over a 7-month time period. Seventy-nine of these patients were between the ages of 
13 and 24 years old. Of these 79 patients, 40 were prescreened for chlamydia using the four 
questions about sexual activity or prior screening for STIs. Two of these 79 patients declined 
chlamydia prescreening and screening. Of the 40 patients, 21 were screened with a clean catch 
urine test for chlamydia. Two of these 21 patients tested positive for chlamydia (See table 1).  






 The 2008 cost for chlamydia in the United States estimated 516.7 million dollars 
(Owusu-Edusei, 2013). In 2012, the costs for pelvic inflammatory disease were estimated at 
$2,000 a person or 1.5 billion healthcare dollars in the United States (Gradison, 2012).  Infertility 
costs were even higher averaging at $6,000 per person (Ditkowsky, Shah, Hammerschlag, 
Kohlhoff, & Smith-Norowitz, 2017). The urgent care charged $95 for the visit, $20 for the urine 
test, and $15 for the antibiotics treating chlamydia. This urgent care visit totaled $130 for a 






After Implementation Prior to Implementation
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chlamydia diagnosis and treatment without insurance. Healthcare costs for untreated chlamydia 
are difficult to estimate however, adopting simple screening recommendations can make a huge 
impact in regard to overall women’s health. 
Conclusion 
Screening for chlamydia should be practiced as routine care in the outpatient setting. 
However, when given the opportunity, urgent care should also utilize dysuria and urinary 
frequency visits to screen for chlamydia cases that would have otherwise been undetected. The 
overall goal for this project was to increase chlamydia prescreening and screening for females, 
ages 15-24, presenting to urgent care with urinary symptoms. Positive chlamydia results could 
have been missed due to the fact that all urine specimens submitted were clean catch with a 72% 
sensitivity instead of a dirty catch or vaginal swabs with an 86% sensitivity. Chlamydia rates 
may have been higher in the study if nucleic acid amplification testing was used and worth 
considering for future screening.  
Implication for Clinical Practice 
The project can impact both providers and patients. The mandated prescreening alerts in 
the EHR will prompt providers to screen for chlamydia when female patient between the ages of 
15 and 24 years old present with UTI symptoms. Sustainability for this practice change is 
encouraged through the four mandatory prescreening questions implemented in the EHR.   
Ideally, the additional screening efforts will also decrease the percentage of chlamydia 
transmission and secondary complications including pelvic inflammatory disease, infertility, 
newborn transmission, and ectopic pregnancies in the future. Screening for chlamydia in females 
with suspected UTIs is a great start but improving sensitivity of the laboratory exam by 
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switching from urine samples to vaginal swabs has the potential of catching and treating more 
cases.  
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